医学
2型糖尿病
内科学
临床试验
仿真
肿瘤科
前瞻性队列研究
糖尿病
2型糖尿病
梅德林
疾病
视网膜病变
作者
Yueh‐Tsung Lee,Jheng‐Yan Wu,T. Chang,Cheng‐Hsien Hung
摘要
AIMS: Chronic ocular diseases such as age-related macular degeneration (AMD) are leading causes of vision loss in older adults. While sodium-glucose co-transporter 2 inhibitors (SGLT2i) are widely prescribed in the management of type 2 diabetes mellitus (T2DM), their effects on ocular disease risk remain largely unknown. MATERIALS AND METHODS: This retrospective cohort study evaluated the association between SGLT2i use and the risk of AMD and other age-related ocular conditions in adults aged ≥60 with T2DM, using a target trial emulation framework based on the TriNetX global health research network (2013-2025). Patients initiating SGLT2i or dipeptidyl peptidase-4 inhibitors (DPP4i) were propensity-matched 1:1. Primary outcomes were incident non-exudative, exudative, and atrophic AMD, and secondary outcomes included cataract, ocular hypertension, and primary open-angle glaucoma. RESULTS: In 12 156 matched patients, SGLT2i use was associated with significantly lower risks of non-exudative AMD (HR 0.64; 95% CI 0.49-0.84) and exudative AMD (HR 0.56; 95% CI 0.33-0.96) compared with DPP4i use. A slight increase in the risk of cataract was observed (HR 1.08; 95% CI 1.02-1.15), while no significant differences were found for atrophic AMD, ocular hypertension, or glaucoma. CONCLUSIONS: These findings suggest that SGLT2i may offer retinal protective effects in older adults with T2DM, supporting further mechanistic and prospective clinical studies.
科研通智能强力驱动
Strongly Powered by AbleSci AI